Amalgamated Bank Decreases Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Amalgamated Bank decreased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 6.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,424 shares of the company’s stock after selling 394 shares during the period. Amalgamated Bank’s holdings in Kymera Therapeutics were worth $138,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of KYMR. Raymond James & Associates boosted its position in shares of Kymera Therapeutics by 7.7% in the third quarter. Raymond James & Associates now owns 26,297 shares of the company’s stock worth $366,000 after buying an additional 1,888 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Kymera Therapeutics by 33.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,183 shares of the company’s stock worth $72,000 after buying an additional 1,310 shares during the period. Arizona State Retirement System purchased a new stake in shares of Kymera Therapeutics in the third quarter worth about $142,000. Barclays PLC boosted its position in shares of Kymera Therapeutics by 1.2% in the third quarter. Barclays PLC now owns 389,476 shares of the company’s stock worth $5,414,000 after buying an additional 4,493 shares during the period. Finally, Swiss National Bank boosted its position in shares of Kymera Therapeutics by 19.7% in the third quarter. Swiss National Bank now owns 79,100 shares of the company’s stock worth $1,099,000 after buying an additional 13,000 shares during the period.

Insider Buying and Selling

In related news, Director Bruce Booth sold 51,184 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $42.85, for a total value of $2,193,234.40. Following the sale, the director now owns 881,266 shares of the company’s stock, valued at approximately $37,762,248.10. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Bruce N. Jacobs sold 3,934 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $41.86, for a total value of $164,677.24. Following the sale, the chief financial officer now owns 142,351 shares of the company’s stock, valued at approximately $5,958,812.86. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bruce Booth sold 51,184 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $42.85, for a total value of $2,193,234.40. Following the completion of the sale, the director now directly owns 881,266 shares in the company, valued at approximately $37,762,248.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 423,529 shares of company stock valued at $17,815,113. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Stock Down 4.1 %

Shares of NASDAQ KYMR opened at $34.24 on Friday. The stock’s 50 day moving average price is $36.88 and its two-hundred day moving average price is $31.73. Kymera Therapeutics, Inc. has a 52-week low of $9.60 and a 52-week high of $45.31. The stock has a market capitalization of $2.10 billion, a P/E ratio of -13.64 and a beta of 2.31.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04. The business had revenue of $10.30 million for the quarter, compared to the consensus estimate of $14.24 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The business’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.70) EPS. On average, analysts anticipate that Kymera Therapeutics, Inc. will post -2.86 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Piper Sandler boosted their price target on Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Oppenheimer cut their price target on Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. JPMorgan Chase & Co. boosted their price target on Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Stifel Nicolaus boosted their price target on Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Wolfe Research assumed coverage on Kymera Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.